Nasdaq · CIK 0001650664
EDIT Editas Medicine, Inc.
Insider trading from SEC Form 4. Last filing 33 d ago. Close $2.90 on Oct 9, 2026, +74% from the 52-week low and -30% from the high.
Last 90 days
Net insider value
-$19k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$19k by 3 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
EDITOct 9, 2026 · close 2.90
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Editas Medicine, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER sell | $2,153 709 shares | -1% | - | |
| 20Weak | Gilmore Neil O'Neill CEO sell | $16k 5,124 shares | -2% | - | |
| 17Weak | Amy Parison SVP, Chief Financial Officer sell | $1,376 453 shares | -3% | - | |
| 10Weak | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER sell | $1,843 710 shares | -1% | +155% from low-37% from high | |
| 20Weak | Gilmore Neil O'Neill CEO sell | $15k 5,592 shares | -2% | +155% from low-37% from high | |
| 17Weak | Amy Parison SVP, Chief Financial Officer sell | $1,189 458 shares | -3% | +155% from low-37% from high | |
| 10Weak | Amy Parison SVP, Chief Financial Officer sell | $1,752 679 shares | -4% | +154% from low-37% from high | |
| 3Weak | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER sell | $13k 5,121 shares | -7% | +156% from low-36% from high | |
| 10Weak | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER sell | $1,252 726 shares | -1% | +86% from low-54% from high | |
| 25Weak | Gilmore Neil O'Neill CEO sell | $26k 15,192 shares | -5% | +86% from low-54% from high | |
| 17Weak | Amy Parison SVP, Chief Financial Officer sell | $769 446 shares | -2% | +86% from low-54% from high | |
| 10Weak | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER sell | $4,946 2,891 shares | -4% | - | |
| 25Weak | Gilmore Neil O'Neill CEO sell | $28k 16,632 shares | -5% | - | |
| 17Weak | Erick Lucera EVP, CHIEF FINANCIAL OFFICER sell | $7,030 4,109 shares | -4% | - | |
| 3Weak | Baisong Mei EVP, CHIEF MEDICAL OFFICER sell | $1,124 541 shares | -0% | - | |
| 13Weak | Gilmore Neil O'Neill CEO sell | $3,361 1,618 shares | -1% | - |
Transactions
The last 29 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Daniel Scott Ory EVP, Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +950,000 | $0.00 | $0 | 950,000 | 33 d ago |
| Sep 3, 2026 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock10b5-1 | -709 | $3.04 | $2,153 | 61,660 | 38 d ago |
| Sep 3, 2026 | Gilmore Neil O'Neill CEO | SOpen-market sale Common Stock10b5-1 | -5,124 | $3.04 | $16k | 243,189 | 38 d ago |
| Sep 3, 2026 | Amy Parison SVP, Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -453 | $3.04 | $1,376 | 13,839 | 38 d ago |
| Sep 3, 2025 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock10b5-1 | -710 | $2.60 | $1,843 | 69,490 | Sep 4, 2025 |
| Sep 3, 2025 | Gilmore Neil O'Neill CEO | SOpen-market sale Common Stock10b5-1 | -5,592 | $2.60 | $15k | 274,690 | Sep 4, 2025 |
| Sep 3, 2025 | Amy Parison SVP, Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -458 | $2.60 | $1,189 | 16,369 | Sep 4, 2025 |
| Aug 7, 2025 | Amy Parison SVP, Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -679 | $2.58 | $1,752 | 16,827 | Aug 8, 2025 |
| Jul 31, 2025 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock10b5-1 | -5,121 | $2.49 | $13k | 64,398 | Aug 4, 2025 |
| Jun 6, 2025 | Bernadette Connaughton director | AGrant or award Stock Option (right to buy)derivative | +37,500 | $0.00 | $0 | 37,500 | Jun 10, 2025 |
| Jun 6, 2025 | Andrew Hirsch director | AGrant or award Stock Option (right to buy)derivative | +37,500 | $0.00 | $0 | 37,500 | Jun 10, 2025 |
| Jun 6, 2025 | Elliott M. Levy director | AGrant or award Stock Option (right to buy)derivative | +37,500 | $0.00 | $0 | 37,500 | Jun 10, 2025 |
| Jun 6, 2025 | David Scadden director | AGrant or award Stock Option (right to buy)derivative | +37,500 | $0.00 | $0 | 37,500 | Jun 10, 2025 |
| Jun 6, 2025 | Jessica Hopfield director | AGrant or award Stock Option (right to buy)derivative | +37,500 | $0.00 | $0 | 37,500 | Jun 10, 2025 |
| Jun 3, 2025 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock10b5-1 | -726 | $1.72 | $1,252 | 69,519 | Jun 4, 2025 |
| Jun 3, 2025 | Amy Parison SVP, Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -446 | $1.72 | $769 | 17,506 | Jun 4, 2025 |
| Jun 3, 2025 | Gilmore Neil O'Neill CEO | SOpen-market sale Common Stock10b5-1 | -15,192 | $1.72 | $26k | 280,282 | Jun 4, 2025 |
| Apr 8, 2025 | Amy Parison SVP, Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +34,672 | $0.00 | $0 | 34,672 | Apr 8, 2025 |
| Mar 8, 2025 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (right to buy)derivative | +275,100 | $0.00 | $0 | 275,100 | Mar 27, 2025 |
| Mar 8, 2025 | Gilmore Neil O'Neill CEO | AGrant or award Stock Option (right to buy)derivative | +828,000 | $0.00 | $0 | 828,000 | Mar 27, 2025 |
| Mar 8, 2025 | Erick Lucera EVP, CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +275,100 | $0.00 | $0 | 275,100 | Mar 27, 2025 |
| Mar 8, 2025 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | AGrant or award Stock Option (right to buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Mar 27, 2025 |
| Mar 8, 2025 | Gilmore Neil O'Neill CEO | AGrant or award Stock Option (right to buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 27, 2025 |
| Mar 8, 2025 | Erick Lucera EVP, CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Mar 27, 2025 |
| Mar 4, 2025 | Linda Burkly EVP, CHIEF SCIENTIFIC OFFICER | SOpen-market sale Common Stock10b5-1 | -2,891 | $1.71 | $4,946 | 70,245 | Mar 5, 2025 |
| Mar 4, 2025 | Gilmore Neil O'Neill CEO | SOpen-market sale Common Stock10b5-1 | -16,632 | $1.71 | $28k | 295,474 | Mar 5, 2025 |
| Mar 4, 2025 | Erick Lucera EVP, CHIEF FINANCIAL OFFICER | SOpen-market sale Common Stock10b5-1 | -4,109 | $1.71 | $7,030 | 112,720 | Mar 5, 2025 |
| Dec 3, 2024 | Baisong Mei EVP, CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -541 | $2.08 | $1,124 | 133,354 | Dec 5, 2024 |
| Dec 3, 2024 | Gilmore Neil O'Neill CEO | SOpen-market sale Common Stock10b5-1 | -1,618 | $2.08 | $3,361 | 312,106 | Dec 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Linda BurklyEVP, CHIEF SCIENTIFIC OFFICER
- Bernadette Connaughtondirector
- Andrew Hirschceo, president, officer, director
- Jessica Hopfielddirector
- Elliott M. Levydirector
- Erick LuceraEVP, CHIEF FINANCIAL OFFICER
- Baisong MeiEVP, CHIEF MEDICAL OFFICER
- Gilmore Neil O'NeillCEO
- Daniel Scott OryEVP, Chief Medical Officer
- Amy ParisonSVP, Chief Financial Officer
- David Scaddendirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.